Monopar Therapeutics (MNPR) Short term Debt (2020)
Monopar Therapeutics (MNPR) posted Short term Debt of $67772.0 for Q3 2020, up 43.04% sequentially from $47379.0 in Q2 2020.
Powered by 
Analysis
Monopar Therapeutics (MNPR) Short term Debt (2020) Analysis & Trends
Monopar Therapeutics has reported Short term Debt for 1 years, with the latest figure at $67772.0 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Monopar Therapeutics | 1.01 Bn | 957.41 Mn | - |